menu
    • menu
    [{"orgOrder":0,"company":"Lotus Pharmaceutical","sponsor":"Corium","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lotus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Lotus Pharmaceutical \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Lotus Pharmaceutical \/ Lotus Pharmaceutical"},{"orgOrder":0,"company":"Lotus Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"TAIWAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lotus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lotus Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lotus Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lotus Pharmaceutical","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Aceclidine Hydrochloride","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lotus Pharmaceutical","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Solution","sponsorNew":"Lotus Pharmaceutical \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Lotus Pharmaceutical \/ Lotus Pharmaceutical"},{"orgOrder":0,"company":"Lotus Pharmaceutical","sponsor":"Klinge Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lotus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lotus Pharmaceutical \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Lotus Pharmaceutical \/ Lotus Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Lotus Pharmaceutical

    Menu

    Lotus Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Aquaexpo
                            Not Confirmed

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : LENZ Therapeutics

                            Deal Size : $125.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LENZ and Lotus Sign License Deal for LNZ100 in Korea and Southeast Asia

                            Details : Under the licensing agreement, Lotus will holds the rights of LNZ100 (Aceclidine HCl) in Korea, which is being evaluated for the treatment of Presbyopia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 09, 2025

                            Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : LENZ Therapeutics

                            Deal Size : $125.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Aquaexpo
                            Not Confirmed

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Recipient : Klinge Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lotus Becomes Strategic Partner for the Commercialization of Biosimilar Ahzantive

                            Details : Through the collaboration, Lotus will lead the commercialization of Ahzantive (Aflibercept) in the designated regions, a biosimilar candidate to Eylea.

                            Product Name : Ahzantive

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            February 05, 2025

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Recipient : Klinge Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Aquaexpo
                            Not Confirmed

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Donepezil

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Corium

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Trea...

                            Details : Under the terms of the agreement, Lotus will have exclusive rights to commercialize Adlarity (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in the applicable territory and will be responsible for the regulatory approval p...

                            Product Name : Adlarity

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 10, 2023

                            Lead Product(s) : Donepezil

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Corium

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Aquaexpo
                            Not Confirmed

                            Lotus Pharmaceutical

                            Taiwan arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metformin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Met...

                            Details : Metformin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 22, 2010

                            Lead Product(s) : Metformin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth